Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=0db3f518-5f0f-4084-8b6f-4ce027f9f671&Preview=1
Date 10/16/2009
Company Name Augmenix
Mailing Address 204 2nd Avenue Waltham, MA 02451
Company Description Augmenix™, Inc. is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Augmenix, Inc.’s initial product will be the first synthetic tissue spacer designed and indicated to reduce radiation exposure of normal tissues adjacent to prostate cancers. Augmenix’s vision is to address unmet patient needs following cancer radiotherapy in a variety of organ systems by developing first-of-a-kind therapeutic products based on proprietary in-situ formed hydrogel technology.
Proceeds Purposes The proceeds will be used to conduct the clinical and commercial development of the SpaceOAR((TM)). System in Europe and the United States, as well as to develop other products in the Augmenix pipeline.
M&A Terms
Venture Investor Ascension Health Ventures
Venture Investor Versant Ventures
Venture Investor Pinnacle Ventures
Venture Investor Catalyst Health & Technology Partners